1. Effect of dapagliflozin as an adjunct to insulin over 52 weeks in individuals with type 1 diabetes: post-hoc renal analysis of the DEPICT randomised controlled trials. Issue 10 (October 2020) Authors: Groop, Per-Henrik; Dandona, Paresh; Phillip, Moshe; Gillard, Pieter; Edelman, Steven; Jendle, Johan; Xu, John; Scheerer, Markus F; Thoren, Fredrik; Iqbal, Nayyar; Repetto, Enrico; Mathieu, Chantal Journal: Lancet Issue: Volume 8:Issue 10(2020) Page Start: 845 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Effects of canagliflozin versus finerenone on cardiorenal outcomes: exploratory post hoc analyses from FIDELIO-DKD compared to reported CREDENCE results. Issue 7 (25th November 2021) Authors: Agarwal, Rajiv; Anker, Stefan D; Filippatos, Gerasimos; Pitt, Bertram; Rossing, Peter; Ruilope, Luis M; Boletis, John; Toto, Robert; Umpierrez, Guillermo E; Wanner, Christoph; Wada, Takashi; Scott, Charlie; Joseph, Amer; Ogbaa, Ike; Roberts, Luke; Scheerer, Markus F; Bakris, George L Journal: Nephrology dialysis transplantation Issue: Volume 37:Issue 7(2022) Page Start: 1261 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Kidney outcomes with finerenone: an analysis from the FIGARO-DKD study. Issue 2 (22nd April 2022) Authors: Ruilope, Luis M; Pitt, Bertram; Anker, Stefan D; Rossing, Peter; Kovesdy, Csaba P; Pecoits-Filho, Roberto; Pergola, Pablo; Joseph, Amer; Lage, Andrea; Mentenich, Nicole; Scheerer, Markus F; Bakris, George L Journal: Nephrology dialysis transplantation Issue: Volume 38:Issue 2(2023) Page Start: 372 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗